Conclusions During lamivudine therapy, there is no relation between the YMDD mutation and the HBV genotypes.
结论拉米夫定治疗期间，HBV的YMDD变异不受病毒基因型的影响。
Conclusion: Patients who withhold lamivudine after YMDD mutation will run great risks, which may lead to hepatic failure.
结论：YMDD变异后停用拉米夫定的患者将冒很大风险，容易导致肝功能肝功能衰竭。
Objective:To observe the efficacy and safety of adefovir dipivoxil(ADV)for chronic hepatitis B(CHB)with YMDD mutation during lamivudine(LAM)therapy.
目的 系统评价与拉米夫定相关的乙型肝炎病毒YMDD区变异后不同抗病毒治疗方法的疗效和安全性。
Methods the serum YMDD mutation, HBV DNA, ALT and HbeAg levels of 60 patients on lamivudine therapy were detected by FQ-PCR, ELISA, and rate method, respectively.
方法采用实时荧光定量pcr、ELISA及速率法分别检测60例乙肝患者经拉米呋啶治疗后其血清YMDD、HBVDNA、乙肝标志物及alt的变化情况。
To set up using the gene chip technology to detect and identify quickly and accurately the HBV P gene YMDD Motif mutation during the chronic hepatitis treated with lamivudine.
建立乙型肝炎病毒变异基因诊断芯片对拉米夫定治疗慢性乙型肝炎过程中出现的肝炎病毒P基因区YMDD变异进行快速准确的检测方法。
To set up using the gene chip technology to detect and identify quickly and accurately the HBV P gene YMDD Motif mutation during the chronic hepatitis treated with lamivudine.
建立乙型肝炎病毒变异基因诊断芯片对拉米夫定治疗慢性乙型肝炎过程中出现的肝炎病毒P基因区YMDD变异进行快速准确的检测方法。
应用推荐